<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880460</url>
  </required_header>
  <id_info>
    <org_study_id>BSMMU/2021/257</org_study_id>
    <nct_id>NCT04880460</nct_id>
  </id_info>
  <brief_title>Assess the Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients for Improvement of Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is 8 weeks, randomized, double-blind, placebo-controlled trial to assess&#xD;
      the effect of magnesium glycinate on symptoms of moderate and severe depression in 90&#xD;
      patients. Participants will be assessed at baseline, 4 weeks, and 8 weeks. Subjects will be&#xD;
      randomized to receive either 400 mg elemental magnesium daily or 400 mg placebo tablet daily&#xD;
      for 8 weeks. The primary outcome is the measure of the DASS21 questionnaire and the secondary&#xD;
      measure includes serum magnesium level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depressive disorder (MDD), is a mood disorder affecting 300 million people worldwide&#xD;
      with a prevalence of 6.7% in Bangladesh. Depression is the main contributor to suicidal&#xD;
      deaths and globally ranked as the single largest contributor to non-fatal health loss.&#xD;
      Various psychological, genetic, environmental, and biochemical factors are presumed to be&#xD;
      involved in the causation of MDD. About 60-70% of individuals with MDD do not achieve&#xD;
      complete remission from symptoms to conventional available anti-depressant medicines. Recent&#xD;
      trials attempted to assess the effect of magnesium in reducing depressive symptoms in MDD&#xD;
      patients. This study evaluates whether there is any role of magnesium in reducing depressive&#xD;
      symptoms between those who did and did not receive magnesium in an 8 weeks period. This&#xD;
      includes 90 major depressive patients who were recruited from psychiatry OPD of BSMMU.&#xD;
      Participants will take either 400 mg elemental magnesium daily in the form of magnesium&#xD;
      glycinate tablet or 400 mg placebo tablet daily for 8 weeks. Initially, baseline serum&#xD;
      magnesium level will be measured and repeated again after 8 weeks of intervention. A baseline&#xD;
      depression survey will be done by DASS21 items and also repeated at 4 weeks and 8 weeks.&#xD;
      DASS21 is a validated set of three self-report scales to measure the state of depression,&#xD;
      anxiety, and stress, where each of the three scales contains 7 items. The depression scale&#xD;
      assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest,&#xD;
      anhedonia, and inertia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Newly diagnosed MDD patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression severity score assessment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assess the severity score of depressive symptoms by DASS-21 (Depression Anxiety and Stress Scale) at baseline, after 4 weeks , and after 8 weeks.&#xD;
And compare the score between two group. DASS21 score range from 0-28+ with the following scores: 0-9 Normal, 10-13 Mild, 14-20 Moderate, 21-27 Severe, 28+ Extremely severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical assessment</measure>
    <time_frame>8 weeks</time_frame>
    <description>Serum magnesium level is assessed at baseline and after 8 weeks intervention. Compare the serum magnesium level between two group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>MDD</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm includes 45 MDD patients receiving SSRIs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm includes 45 MDD patients receiving SSRIs</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium Glycinate tablet 200mg</intervention_name>
    <description>Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo tablet 200mg</intervention_name>
    <description>Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed and untreated MDD patients diagnosed the Psychiatry department of&#xD;
             BSMMU&#xD;
&#xD;
          -  Age: 18 to 60 years&#xD;
&#xD;
          -  Sex: both male and female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age: &lt;18 years and &gt;60 years&#xD;
&#xD;
          -  Patients receiving dietary supplements in the last two months&#xD;
&#xD;
          -  Patients having any other psychological disorders (such as anxiety disorder,&#xD;
             schizophrenia, bipolar disorder, alcoholism) and any other medical conditions&#xD;
&#xD;
          -  Patients having a serious cognitive defect that causes disturbance of communication&#xD;
&#xD;
          -  Pregnancy and lactation during last year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Md. Sayedur Rahman, MBBS, MPhil</last_name>
    <role>Study Chair</role>
    <affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarmin Sultana, MBBS</last_name>
    <phone>01713924904</phone>
    <email>dr.sarmin.kmc@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prof. Md. Sayedur Rahman, MBBS, MPhil</last_name>
    <phone>01971840757</phone>
    <email>srkhasru@bsmmu.edu.bd</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Basic Science and Paraclinical Science of BSMMU</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarmin Sultana, MBBS</last_name>
      <phone>01713924904</phone>
      <email>dr.sarmin.kmc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Prof. Md. Sayedur Ul Rahman, MBBS, MPhil</last_name>
      <phone>01971840757</phone>
      <email>srkhasru@bsmmu.edu.bd</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>September 25, 2021</last_update_submitted>
  <last_update_submitted_qc>September 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Dr. Sarmin Sultana</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>MDD</keyword>
  <keyword>Magnesium</keyword>
  <keyword>DASS21</keyword>
  <keyword>Serum magnesium level</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

